28
Cytogenetic Analysis in Hematological Malignancies Hwei-Fang Tien, National Taiwan University Hospital

Cytogenetic Analysis in Hematological Malignancies

  • Upload
    spa718

  • View
    195

  • Download
    1

Embed Size (px)

Citation preview

Page 1: Cytogenetic Analysis in Hematological Malignancies

Cytogenetic Analysis in

Hematological Malignancies

Hwei-Fang Tien, National Taiwan University Hospital

Page 2: Cytogenetic Analysis in Hematological Malignancies

Cytogenetics in Hematological Malignancies

• Most patients with hematological malignancies have clonal chromosomal abnormalities.

• Some recurrent chromosomal abnormalities are tumor- and even subtype-specific, so are good for diagnosis and classification.

• The pattern of chromosomal aberrations may predict treatment response and clinical outcome and is good for risk stratification.

• Genes located at the breakpoints of the recurrent abnormalities play an important role in the process of tumorigenesis and can be the target of treatment.

Page 3: Cytogenetic Analysis in Hematological Malignancies

Purpose of Cytogenetic Study in Hematological malignancies

1. Diagnosis and classification

2. Risk stratification

3. Selection of proper treatment

4. Follow-up of the response

Page 4: Cytogenetic Analysis in Hematological Malignancies

Recurrent chromosomal abnormalities in Hematological malignancies

CML t(9;22)

AML t(8;21), t(15;17), inv(16), t(9;11), inv(3), t(6;9), t(1;22), -5/5q-, -7/7q-

ALL t(4;11), t(1;19), t(v;11q23), t(12;21)

MDS -5/del(5q), del(20q); -7/del(7q), +8

Lymphoma DLBCL t(3q27)

Burkitt t(8;14) and variant

Follicular t(14;18)

Mantle cell t(11;14)

Marginal zone t(11;18), t(1;14), t(14;18)

Page 5: Cytogenetic Analysis in Hematological Malignancies

Case Demonstration

Diagnosis

Page 6: Cytogenetic Analysis in Hematological Malignancies

BM smears in a patient with bleeding tendency

NTUH, Gene Chromosome Cancer, 1995,12:161

23Y/O, male , PB plt, 3000/μL; Hb, 9.2 gm/dL; WBC, normal

Plt count increased to 533x103/μL after steroid treatment, but dropped again 1 mo later.

BM smears

Page 7: Cytogenetic Analysis in Hematological Malignancies

BM smears

Page 8: Cytogenetic Analysis in Hematological Malignancies

Cytogenetic Abnormalities

NTUH, Gene Chromosome Cancer, 1995,12:161

The pt received splectomy. Final dignosis: hepatosplenic Tγ/δ lymphoma

A new cytogentc- clinicopathological entity of NHL

Page 9: Cytogenetic Analysis in Hematological Malignancies

NK-cell large granular lymphocytosis

NTUH, Br J Haematol, 1998, 103:1124

Cytogenetic Abnormalities

Diagnosis: NK-cell large granular lymphocyte leukemia

PB smears

Page 10: Cytogenetic Analysis in Hematological Malignancies

Differential diagnosis of hypoplastic MDS with AA

BM smears

Page 11: Cytogenetic Analysis in Hematological Malignancies

Name: 林 X 榮 , 46, XY, -7 [20]

Chromosomal abnormality

Diagnosis: hypoplastic MDSNTUH, Leukemia, 2008, 22:544

Page 12: Cytogenetic Analysis in Hematological Malignancies

Case Demonstration

For Lymphoma Staging

Page 13: Cytogenetic Analysis in Hematological Malignancies

BM study for staging in a patients with DLBCL

Pathol exam. of the BM biopsy specimen: no lymphoma involvement

BM smears

Page 14: Cytogenetic Analysis in Hematological Malignancies

BM smears

Page 15: Cytogenetic Analysis in Hematological Malignancies

Same clonal chromosomal abnormalities in bone marrow as in lymph node

Lymph node Bone marrow

DLBCL stage IV with BM involvement is confirmed

Page 16: Cytogenetic Analysis in Hematological Malignancies

Risk Stratification

Page 17: Cytogenetic Analysis in Hematological Malignancies

AML: Impact of Cytogenetics based on 2008 WHO Classification

Medical Research Council , United Kingdom Blood. 2010;116(3):354 , Blood Rev, 2011; 25:39

t(9;22)-7/7q--5/5q-Inv(3), t(3;3)

t(9;11)t(3;5)t(6;9)MDS-relatedother t(11q23)

t(15;17)

t(8;21)Inv(16)

5876 patients

Normal

Page 18: Cytogenetic Analysis in Hematological Malignancies

MDS: New Cytogenetic Scoring System (n=2,754)

Abnormality Overall survival

AML transformation

Prognostic Subgroup

No. ofPts

% Single Double Cplx Median(months)

Median (months)

Very good 81 2.9 del(11q), -Y ― ―

60.8 NR

Good (reference)

1,809 65.7 Normal, del(5q)del(12p), del(20q)

Including del(5q)

48.6 NR

Intermediate 529 19.2 del(7q), +8, i(17q)+19, any otherIndependent clones

Any other ―

26.0 78.0

Poor 148 5.4 Inv(3)/t(3q)/del(3q),-7

Including-7/del(7q)

3 15.8 21.0

Very poor 187 6.8 ― ― > 3 5.9 8.2

Abbreviations: AML, acute myeloid leukemia; NR, not reached.

Schanz et al, J Clin Oncol, 2012

Page 19: Cytogenetic Analysis in Hematological Malignancies

MM: Impact of genomic aberrations on OS

Avet-Loiseau et al, Blood. 2007;109:3489

Page 20: Cytogenetic Analysis in Hematological Malignancies

Implication of cytogenetics on survival in MM

overall survival (month)

2001000

Cum

ulat

ive

Sur

viva

l

1.0

.8

.6

.4

.2

0.0

Hyperdipolidy (n=19)

Non-hyperdiploid (n=25)

p=0.025

overall survival (month)2001000

Cum

ulati

ve S

urvi

val

1.0

.8

.6

.4

.2

0.0

Normal karyotype (n=106)

Abnormal karyotype (n=44)

P=0.029

NTUH, Ann Oncol 16:1530, 2005

Page 21: Cytogenetic Analysis in Hematological Malignancies

overall survival (month)

2001000

Cum

ulat

ive

Sur

viva

l

1.0

.8

.6

.4

.2

0.0

FISH_∆13 only, N=23

Without abnormality, N=57

p=0.013

CG_∆13N=8

Survival Analysis:

Combined cytogenetics & FISH

NTUH, Ann Oncol 16:1530, 2005

Page 22: Cytogenetic Analysis in Hematological Malignancies

Prognostic relevance of chromosome aberrations in CLL

Zenz & Dohner, Best Pract Res Clin Haematol. 2007 20:439

17p-

11q-

+12

13q- sole

normal

Page 23: Cytogenetic Analysis in Hematological Malignancies

Implications of 17p-/11q- on OS in CLL

Cytogenetics

FISH

NTUH, Ann Hema, 2013, in press

Page 24: Cytogenetic Analysis in Hematological Malignancies

Follow Up the Clinical Course

Page 25: Cytogenetic Analysis in Hematological Malignancies

Chronic Myeloid Leukemia, Chronic Phase

Page 26: Cytogenetic Analysis in Hematological Malignancies

CML in blast crisis

Page 27: Cytogenetic Analysis in Hematological Malignancies

Indication of Cytogenetic Study

• Unknown cause of cytopenia• Fever of unknown origin• WHO classification of AML and ALL• MDS diagnosis and classification (IPSS, IPSS-R)• Lymphoma diagnosis, classification and

staging work up• Risk stratification of CLL and MM• Follow-up of treatment response